Navigation Links
Topaz Pharmaceuticals Names Dr. Mark Strobeck Chief Business Officer
Date:1/10/2011

HORSHAM, Pa., Jan. 10, 2011 /PRNewswire/ -- Topaz Pharmaceuticals Inc., a privately held specialty pharmaceutical company focused on dermatology and pediatrics, today announced that Mark Strobeck, Ph.D., has been appointed vice president and chief business officer. In his new role Dr. Strobeck will report to Robert Radie, president and chief executive officer, and will be responsible for managing business development, corporate strategy and financings.

"We are pleased to welcome to the Topaz management team Mark, a proven leader with a significant track record of success, who will lead our business development efforts," said Robert Radie, president and chief executive officer of Topaz. "With our lead product candidate nearing the final stage of development, we are building our commercial capabilities and interested in extending our business development reach."

Dr. Strobeck has decades of experience in the pharmaceutical and financial industry. Most recently, he served as chief business officer of Trevena, Inc., a pharmaceutical company dedicated to the discovery and development of GPCR biased ligands. Before joining Trevena he served as vice president of business development at GlaxoSmithKline (GSK) where he led the business development efforts for the company's clinical and preclinical stage assets. He also served as vice president of business development for the center of excellence for external drug discovery, a research and development division within GSK. Prior to this role Dr. Strobeck was a principal at SR One Ltd., the wholly owned venture capital arm of GSK.

Dr. Strobeck earned a Ph.D. in pharmacology and cell biophysics from the University of Cincinnati. He completed a post-doctoral fellowship in cardiovascular medicine at the University of Pennsylvania and has a bachelor's degree from St. Lawrence University.

About Topaz Pharmaceuticals Topaz Pharmaceuticals Inc. is a privately held specialty pharmaceutical company focused on developing and commercializing treatments primarily for pediatric and dermatology markets. The company's lead investigational product is a topical cream formulation of ivermectin currently under development for the treatment of head lice in children and adults which affects between six and 12 million people every year. The company has recently concluded two phase 3 studies of ivermectin for this potential indication and expects to file a new drug application this year. Topaz, headquartered in Horsham, PA, is backed by top-tier investors including Aisling Capital and Fidelity Biosciences. For more information about Topaz Pharmaceuticals Inc., please visit www.topazpharma.com. Contact Information E. Blair Schoeb Tel: 908-277-0386 blair@biotechcomm.com
'/>"/>

SOURCE Topaz Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Schiffrin Barroway Topaz & Kessler, LLP and Janet Jenner & Suggs, LLC Comment on Conagra Advisory Regarding Pot Pies Linked to Salmonella Outbreak
2. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
4. TOPAZ Technologies and Tecniplast USA Launch RFID Mobile Census
5. Topaz Pharmaceuticals Announces Positive Data from Topical Ivermectin Trials Presented at Society of Pediatric Dermatology
6. Shareholder Class Action Filed Against SciClone Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
7. TOPAZ Technologies and ML Weekes & Company Announce Partnership
8. Topaz Pharmaceuticals Names Bob Radie Chief Executive Officer
9. Topaz Pharmaceuticals Announces Completion of Pivotal Phase 3 Trials of Ivermectin Topical Cream
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... development of Physiocrine-based therapeutics to address severe, rare diseases, today announced ... upcoming BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay ... December 14, 2016, at 4:20 p.m. ET. About ... ...
(Date:12/9/2016)... , Dec. 9, 2016 Department of Health ... regulations for medical marijuana dispensaries under Act 16 are ... , and are now available online . ... in the plan for operation; process for dispensing medical ... well as where the dispensary facilities can be located," ...
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development continuity to its innovative Unified Instance Manager architecture, meeting the needs ... this new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, ...
Breaking Medicine News(10 mins):